Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 3

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 2(5)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04849728Phase 3Active Not Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Role: lead

NCT03459079Phase 2Completed

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Role: collaborator

NCT05651724Recruiting

Global Research Initiative for Patients Screening on MASH

Role: collaborator

NCT05232071Phase 2Completed

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Role: lead

NCT03008070Phase 2Completed

Phase 2b Study in NASH to Assess IVA337

Role: lead

NCT03370653Phase 2Completed

A Study in MPS VI to Assess Safety and Efficacy of Odiparcil

Role: lead

NCT03866369Phase 1Completed

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

Role: lead

NCT02503644Phase 2Completed

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Role: lead

All 8 trials loaded